Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 18, 2015 4:32 AM ET

Pharmaceuticals

Company Overview of Merck Research Laboratories

Company Overview

Merck Research Laboratories discovers and develops medicines for cancer and neurodegenerative disorders. The company was founded in 2004 and is based in Boston, Massachusetts. Merck Research Laboratories operates as a subsidiary of Merck & Co. Inc.

33 Avenue Louis Pasteur

Boston, MA 02115

United States

Founded in 2004

Phone:

617-992-2000

Key Executives for Merck Research Laboratories

President
Age: 62
Senior Vice President and Franchise Head of Immunology Respiratory & Endocrine
Age: 60
Senior Vice President and Franchise Head of Diabetes & Obesity
Senior Vice President and Head of Franchise
Age: 58
Head of Site
Age: 59
Compensation as of Fiscal Year 2014.

Merck Research Laboratories Key Developments

Merck Research Laboratories Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 09:30 AM

Merck Research Laboratories Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 09:30 AM. Venue: Kerry Hotel, Pudong, Shanghai, China. Speakers: Yongkui Sun, Scout, Greater China, Business Development and Licensing.

Merck Research Laboratories Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 08:55 AM

Merck Research Laboratories Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 08:55 AM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Ji Li, Vice President, Business Development and Licensing.

BIND Therapeutics, Inc. Announces Agreement with Merck to Develop Targeted Accurin Nanomedicines for Oncology

BIND Therapeutics, Inc. announced a joint research and development agreement with Merck, through a subsidiary to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio. The first two Merck compounds include a kinesin spindle protein (KSP) inhibitor and a polo-like kinase 1 (PLK1) inhibitor. Both KSP and PLK1 are regulators of cellular mitosis and are considered essential to the proliferation of cancer cells. These pathways have proven difficult to target effectively using conventional agents due to therapeutic index limitations. Under the terms of the agreement, BIND will apply its Medicinal Nanoengineering(R) platform to develop targeted Accurins based initially on Merck-supplied investigational KSP and PLK1 inhibitors. The agreement also includes the option to incorporate additional Merck compounds in the future. BIND will fund and conduct research and development activities to advance Accurin product candidates based on these agents through first-in-human clinical studies, after which Merck and BIND will alternate in choosing whether or not to further develop and commercialize the Accurin products. If BIND opts in, in most scenarios there will be no payments made to Merck beyond a royalty on future product sales. If Merck opts in, it will pay BIND a fee based on a multiple of BIND's research and development expenses, plus a royalty on future product sales. Further terms of the agreement were not disclosed.

Similar Private Companies By Industry

Company Name Region
Ultra laboratories, Inc. United States
Aton Pharma, Inc. United States
Alcon Research, Ltd. United States
Natural Planet USA, Inc. United States
Redwood Scientific Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Merck Research Laboratories, please visit www.merck.com/mrl. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.